Small Molecule Innovator CDMO Market Size Report by Product (Small Molecule API, Small Molecule Drug Product), Stage Type, Customer Type, Therapeutic Area, Region, and Segment Forecasts, 2024-2030
March 15, 2024 05:41 ET
|
Research and Markets
Dublin, March 15, 2024 (GLOBE NEWSWIRE) -- The "Global Small Molecule Innovator CDMO Market Size, Share & Trends Analysis Report by Product (Small Molecule API, Small Molecule Drug Product),...
$69.7 Billion Oral Solid Dosage Contract Manufacturing Market Assessment 2024-2034 Featuring Lonza Group, Catalent, Recipharm
March 13, 2024 12:00 ET
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Global Oral Solid Dosage Contract Manufacturing Market by Product Type, by Mechanism, by End-User, and By Region" report has been added to ...
Rentschler Biopharma Takes Home the Gold in 20th Annual Team Massachusetts Economic Impact Awards
March 13, 2024 09:30 ET
|
Rentschler Biopharma SE
Company honored with highest award for Central Massachusetts regionNew state-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) facility slated to open for business later this year ...
AVID ALERT: Bragar Eagel & Squire, P.C. is Investigating Avid Bioservices, Inc. on Behalf of Avid Stockholders and Encourages Investors to Contact the Firm
March 07, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Avid Bioservices, Inc....
SHAREHOLDER ALERT: Avid Bioservices Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
March 07, 2024 11:43 ET
|
Block & Leviton LLP
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Avid Bioservices, Inc. (NASDAQ: CDMO) for potential securities law violations. Investors who have lost money in their...
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
March 06, 2024 23:58 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing...
Avid Bioservices Announces Proposed Private Placement of Convertible Notes
March 06, 2024 16:32 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it...
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
March 06, 2024 16:31 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023
March 06, 2024 04:00 ET
|
Rentschler Biopharma SE
Exceptional capabilities in guiding therapies from early-stage development through to market based on over 50 years of biotech experience LAUPHEIM, Germany and MILFORD, Mass. and STEVENAGE, United...
Pharmaceutical Quality Management Systems Markets: Deviation, CAPA, Audit, Risk & Compliance, Inspection, Document, Change, Training Management - Global Forecast to 2030
March 01, 2024 04:46 ET
|
Research and Markets
Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Pharmaceutical Quality Management Systems Market by Solution Type (Deviation, CAPA, Audit, Risk & Compliance, Inspection, Document, Change,...